Stakeholder Perspectives on the Rapidly Advancing Chemotherapy Landscapes for Triple-Negative Breast Cancer
In the metastatic breast cancer sphere, 2 chemotherapy agents have come to the forefront: capecitabine, for metastatic breast cancer, and eribulin, for triple-negative breast cancer.
Assessing the Changing Treatment Landscape in Triple-Negative Breast Cancer
Treatment options for triple-negative breast cancer are historically limited; however, recent developments regarding the use of targeted therapies and various combination regimens have broadened the treatment spectrum and ushered in new clinical approaches.
Dr. Gligorov on Potential Challenges of Utilizing PARP Inhibitors in TNBC
Joseph Gligorov, MD, PhD, discusses potential challenges of utilizing PARP inhibitors in triple-negative breast cancer.
Dr. Crown on the Role of Eribulin Mesylate in TNBC
John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.
Dr. Brufsky on the Future Role of Chemotherapy in TNBC
Adam M. Brufsky, MD, PhD, discusses the future role of chemotherapy in triple-negative breast cancer.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512